Novartis AG
BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, CD19-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND COMBINATION THERAPIES
Last updated:
Abstract:
The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to a method of administering a BCMA-targeting chimeric antigen receptor (CAR) therapy and an additional therapeutic agent.
Status:
Application
Type:
Utility
Filling date:
15 Nov 2018
Issue date:
19 Nov 2020